News Sandoz buys into Durect's long-acting painkiller Sandoz has signed a potential $293 million agreement to develop and market Durect’s Posimir, an extended-release, locally-acting, non-opioid painkiller in the US.
News Novartis takes option on NASH drug from Conatus Swiss pharma takes option on FXR agonist emricasan.
News Valeant's Siliq price undercuts rivals to offset black box w... Siliq will be cheaper than rivals from Novartis and Eli Lilly.
News Novartis and Allergan to combine drugs in NASH Swiss pharma also aims for new CAR-T therapy indication.
News Novartis takes aim at Shire and Allergan with dry-eye drug Swiss company takes option on Lubris' ECF843.
News Kite keeps pressure on Novartis with CAR-T filing Kite completes filing a day after rival Novartis.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.